Literature DB >> 15313904

Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells.

Cristina Agbunag1, Dafna Bar-Sagi.   

Abstract

We have established a primary pancreatic duct epithelial cell culture (PDEC) system to investigate the relationship between oncogenic activation of K-ras and pancreatic ductal tumorigenesis. We have found that the acute introduction of physiological levels of oncogenic K-ras (K-rasV12) into quiescent PDECs stimulates S-phase entry and induces a pronounced increase in cell size. Both effects are dependent on the functional integrity of the phosphatidylinositol 3'-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway. In addition, K-rasV12 promotes the loss of epithelial E-cadherin and the gain of mesenchymal N-cadherin in PDEC. Our observations indicate that the oncogenic activation of K-ras is sufficient to elicit mitogenic and morphogenic responses in pancreatic ductal cells and hence is likely to play an instructive role in the initiation of pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313904     DOI: 10.1158/0008-5472.CAN-04-0807

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.

Authors:  Kyoung Eun Lee; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 2.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

Authors:  Riccardo Ferro; Marco Falasca
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.

Authors:  Olga K Mirzoeva; Byron Hann; Yun K Hom; Jayanta Debnath; Dana Aftab; Kevan Shokat; W Michael Korn
Journal:  J Mol Med (Berl)       Date:  2011-06-16       Impact factor: 4.599

4.  IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.

Authors:  Maria Noé Garcia; Daniel Grasso; Maria Belen Lopez-Millan; Tewfik Hamidi; Celine Loncle; Richard Tomasini; Gwen Lomberk; Françoise Porteu; Raul Urrutia; Juan L Iovanna
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

Review 5.  Genomic alterations in pancreatic cancer and their relevance to therapy.

Authors:  Erina Takai; Shinichi Yachida
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

6.  Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D.

Authors:  Niels Smakman; Diana J M van den Wollenberg; Inne H M Borel Rinkes; Rob C Hoeben; Onno Kranenburg
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.

Authors:  Victoria A Appleman; Leanne G Ahronian; JiuFeng Cai; David S Klimstra; Brian C Lewis
Journal:  Mol Cancer Res       Date:  2012-08-07       Impact factor: 5.852

8.  Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.

Authors:  Shao-Jie Chen; Yin-Ting Chen; Lin-Juan Zeng; Qiu-Bo Zhang; Guo-da Lian; Jia-Jia Li; Ke-Ge Yang; Chu-Mei Huang; Ya-Qing Li; Zhong-Hua Chu; Kai-Hong Huang
Journal:  Tumour Biol       Date:  2016-03-08

Review 9.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

10.  An improved primary culture system of pancreatic duct epithelial cells from Wistar rats.

Authors:  Ke-Ling Chen; Xue-Lian Zheng; Yuan Li; Lie Yang; Zong-Guang Zhou; Xiang-Yu Zhou; Bin Zhou; Rong Wang; Jing-Jing Jiang; Li-Hui Chen; Lan Zhan
Journal:  Cytotechnology       Date:  2009-07       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.